Cancer molecular Dx firm seeks to obtain $6.6 million

12/24/2012 | GenomeWeb Daily News (free registration)

Epigenomics hopes to obtain $6.6 million in a funding round it plans to launch next month. The company is the maker of the Epi proColon test, a blood-based assay for screening colorectal cancer. Proceeds from the planned fundraising will be used to finance the company's operations as well as expand its capabilities for product distribution.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA